SEC Form 4
PharmaCyte Biotech, Inc. (PMCB) insider trading
In the 12 months to Oct 26, 2026, 2 PMCB insiders reported open-market purchases of $128.7K across 2 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $128.7K
- 2 filings
Who traded PMCB, and when
- Purchase
PMCB daily close from Oct 27, 2025 to Oct 26, 2026, between $0.34 and $1.22, last $0.35. 0 sale and 2 purchase filings by 2 insiders, marked at their filing dates. Joshua Silverman, CEO and President: bought $80.5K across 1 filing, first filed Jan 7, 2026, last Jan 7, 2026. Jonathan Schechter, Director: bought $48.2K across 1 filing, first filed Jan 7, 2026, last Jan 7, 2026.
Largest mark · tap a row for others
Joshua Silverman · CEO and President
Purchase $80,476
100,000 shares at $0.80 avg
Filed Jan 7, 2026 · traded Jan 5
Close on filing date $0.83
Joshua Silverman · CEO and President
CEO and President
$80.5K boughtJonathan Schechter · Director
Director
$48.2K boughtOpen-market trades
2 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Joshua Silverman | CEO and President | — | $80.5K | 1 | — | |
| Jonathan Schechter | Director | — | $48.2K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Jonathan Schechter Director | Purchase | 60,000 | $0.80 | $48.2K | 192,500 | |
traded | Joshua Silverman CEO and President | Purchase | 100,000 | $0.80 | $80.5K | 416,250 |
GET /stocks/filings/vX/form-4?tickers=PMCB&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"PMCB"
],
"issuer_cik": "0001157075",
"owner_cik": "0001524858",
"accession_number": "0001683168-26-000148",
"form_type": "4",
"filing_date": "2026-01-07",
"period_of_report": "2026-01-05",
"issuer_name": "PharmaCyte Biotech, Inc.",
"issuer_trading_symbol": "PMCB",
"owner_name": "Silverman Joshua",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "CEO and President",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-01-06",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 30000,
"transaction_price_per_share": 0.7889,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 376250,
"transaction_value": 23667,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"remarks": "Exhibit 24.1, Power of Attorney"
},
{
"tickers": [
"PMCB"
],
"issuer_cik": "0001157075",
"owner_cik": "0001619259",
"accession_number": "0001683168-26-000147",
"form_type": "4",
"filing_date": "2026-01-07",
"period_of_report": "2026-01-05",
"issuer_name": "PharmaCyte Biotech, Inc.",
"issuer_trading_symbol": "PMCB",
"owner_name": "SCHECHTER JONATHAN",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-01-07",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 20000,
"transaction_price_per_share": 0.8436,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 192500,
"transaction_value": 16872,
"not_subject_to_section_16": false,
"direct_or_indirect": "D"
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 10 records
- Tax withholding5 records
- Grants and awards5 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has PharmaCyte Biotech, Inc.'s CEO sold stock?
No. Joshua Silverman (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is PMCB’s insider data?
These are PMCB Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track PMCB insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for PMCB every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.